Minamestane

Minamestane (INN (former developmental code name FCE-24,928) is a steroidal aromatase inhibitor which was under development by Farmitalia-Carlo Erba as an antineoplastic agent in the mid-1990s but was never marketed.[1][2][3]

Minamestane
Clinical data
ATC code
  • None
Identifiers
IUPAC name
  • 4-aminoandrosta-1,4,6-triene-3,17-dione
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H23NO2
Molar mass297.398 g·mol−1
3D model (JSmol)
SMILES
  • O=C4\C=C/[C@]3(C(/C=C\[C@H]2[C@H]1[C@@](C(=O)CC1)(CC[C@@H]23)C)=C4/N)C
InChI
  • InChI=1S/C19H23NO2/c1-18-10-8-15(21)17(20)14(18)4-3-11-12-5-6-16(22)19(12,2)9-7-13(11)18/h3-4,8,10-13H,5-7,9,20H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1
  • Key:DAKHYLIFCYPHQW-KZQROQTASA-N

Unlike other steroidal aromatase inhibitors such as formestane and exemestane, minamestane does not have androgenic properties.[2]

See also

References
  1. F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1357. ISBN 978-0-412-46630-4. Retrieved 20 May 2012.
  2. Di Salle E, Briatico G, Giudici D, et al. (June 1994). "Novel aromatase and 5 alpha-reductase inhibitors". The Journal of Steroid Biochemistry and Molecular Biology. 49 (4–6): 289–94. doi:10.1016/0960-0760(94)90270-4. PMID 8043491. S2CID 54350143.
  3. Combs, Donald W (1995). "Review Oncologic, Endocrine & Metabolic: Recent developments in aromatase inhibitors". Expert Opinion on Therapeutic Patents. 5 (6): 529533. doi:10.1517/13543776.5.6.529. ISSN 1354-3776.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.